ERBB4 and breast cancer: In conclusion, our study shows that one pharmacodiagnostic antibody can bind HER4 protein and peptide in IHC, ELISA and immunoblots, suggesting that it could also bind to the intracellular domain of HER4 in clinical breast cancer samples.